Tetrazepam (is marketed under the following brand names, Clinoxan, Epsipam, Myolastan, Musaril, Relaxam and Spasmorelax) is a benzodiazepine derivative with anticonvulsant, anxiolytic, muscle relaxant and slightly hypnotic properties. It was formerly used mainly in Austria, France, Belgium, Germany and Spain to treat muscle spasm, anxiety disorders such as panic attacks, or more rarely to treat depression, premenstrual syndrome or agoraphobia. Tetrazepam has relatively little sedative effect at low doses while still producing useful muscle relaxation and anxiety relief. The Co-ordination Group for Mutual Recognition and Decentralised Procedures-Human (CMD(h)) endorsed the Pharmacovigilance Risk Assessment Committee (PRAC) recommendation to suspend the marketing authorisations of tetrazepam-containing medicines across the European Union (EU) in April 2013. The European Commission has confirmed the suspension of the marketing authorisations for Tetrazepam in Europe because of cutaneous toxicity, effective from the 1 August 2013.
Tetrazepam is used therapeutically as a muscle relaxant.
The indicated adult dose for muscle spasm is 25 mg to 150 mg per day, increased if necessary to a maximum of 300 mg per day, in divided doses. Tetrazepam is not generally recommended for use in children, except on the advice of a specialist.
Allergic reactions to tetrazepam occasionally occur involving the skin.
Allergic reactions can develop to tetrazepam and it is considered to be a potential allergen. Drug rash and drug-induced eosinophilia with systemic symptoms is a known complication of tetrazepam exposure. These hypersensitive allergic reactions can be of the delayed type.
Patch testing has been used successfully to demonstrate tetrazepam allergy. Oral testing can also be used. Skin prick tests are not always accurate and may produce false negatives.
Drowsiness is a common side effect of tetrazepam. A reduction in muscle force can occur.Myasthenia gravis, a condition characterised by severe muscle weakness is another potential adverse effect from tetrazepam. Cardiovascular and respiratory adverse effects can occur with tetrazepam similar to other benzodiazepines.
Tetrazepam, like other benzodiazepines is a drug which is very frequently present in cases of overdose. These overdoses are often mixed overdoses, i.e. a mixture of other benzodiazepines or other drug classes with tetrazepam.
Contraindications and special caution
Benzodiazepines require special precaution if used in the elderly, during pregnancy, in children, alcohol or drug-dependent individuals and individuals with comorbidpsychiatric disorders.
Tetrazepam is an unusual benzodiazepine in its molecular structure as it has cyclohexenyl group which has substituted the typical 5-phenyl moiety seen in other benzodiazepines.
Tetrazepam, is rapidly absorbed after oral administration, within 45 mins and reaches peak plasma levels in less than 2 hours. It is classed as an intermediate acting benzodiazepine with an elimination half-life of approximately 15 hours. It is primarily metabolised to the inactive metabolites 3-hydroxy-tetrazepam and nortetrazepam. The pharmacological effects of tetrazepam are significantly less potent when compared against diazepam, in animal studies. Tetrazepam is a benzodiazepine site agonist and binds unselectively to type 1 and type 2 benzodiazepine site types as well as to peripheral benzodiazepine receptors. The muscle relaxant properties of tetrazepam are most likely due to a reduction of calcium influx. Small amounts of diazepam as well as the active metabolites of diazepam are produced from metabolism of tetrazepam. The metabolism of tetrazepam has led to false accusations of prisoners prescribed tetrazepam of taking illicit diazepam; this can lead to increased prison sentences for prisoners.
Tetrazepam as with other benzodiazepines is sometimes abused. It is sometimes abused to incapacitate a victim in order to carry out a drug-facilitated crime. or abused in order to achieve a state of intoxication.
Tetrazepam's abuse for to carry out drug facilitated crimes may be less however, than other benzodiazepines due to its reduced hypnotic properties.
^Simiand J, Keane PE, Biziere K, Soubrie P (January 1989). "Comparative study in mice of tetrazepam and other centrally active skeletal muscle relaxants". Archives Internationales de Pharmacodynamie et de Therapie. 297: 272–85. PMID2567153.
^Rode G, Maupas E, Luaute J, Courtois-Jacquin S, Boisson D (May 2003). "[Medical treatment of spasticity]". Neuro-Chirurgie. 49 (2–3 Pt 2): 247–55. PMID12746699.
^Lobisch M, Schaffler K, Wauschkuhn H, Nickel B (March 1996). "[Clinical pilot study of the myogenic effects of flupirtine in comparison to tetrazepam and placebo]". Arzneimittel-Forschung. 46 (3): 293–8. PMID8901152.
^Baumgärtner MG, Cautreels W, Langenbahn H (1984). "Biotransformation and pharmacokinetics of tetrazepam in man". Arzneimittel-Forschung. 34 (6): 724–9. PMID6148954.
^Keane PE, Simiand J, Morre M, Biziere K (May 1988). "Tetrazepam: a benzodiazepine which dissociates sedation from other benzodiazepine activities. I. Psychopharmacological profile in rodents". The Journal of Pharmacology and Experimental Therapeutics. 245 (2): 692–8. PMID2896794.
^Keane PE, Bachy A, Morre M, Biziere K (May 1988). "Tetrazepam: a benzodiazepine which dissociates sedation from other benzodiazepine activities. II. In vitro and in vivo interactions with benzodiazepine binding sites". The Journal of Pharmacology and Experimental Therapeutics. 245 (2): 699–705. PMID2896795.
^Pérez-Guerrero C, Suárez J, Herrera MD, Marhuenda E (May 1997). "Spasmolytic effects of tetrazepam on rat duodenum and guinea-pig ileum". Pharmacological Research. 35 (5): 493–7. doi:10.1006/phrs.1997.0173. PMID9299217.
^Baumann A, Lohmann W, Schubert B, Oberacher H, Karst U (April 2009). "Metabolic studies of tetrazepam based on electrochemical simulation in comparison to in vivo and in vitro methods". Journal of Chromatography A. 1216 (15): 3192–8. doi:10.1016/j.chroma.2009.02.001. PMID19233363.
^Schubert B, Pavlic M, Libiseller K, Oberacher H (December 2008). "Unraveling the metabolic transformation of tetrazepam to diazepam with mass spectrometric methods". Analytical and Bioanalytical Chemistry. 392 (7–8): 1299–308. doi:10.1007/s00216-008-2447-4. PMID18949465. S2CID10967477.
^Concheiro M, Villain M, Bouchet S, Ludes B, López-Rivadulla M, Kintz P (October 2005). "Windows of detection of tetrazepam in urine, oral fluid, beard, and hair, with a special focus on drug-facilitated crimes". Therapeutic Drug Monitoring. 27 (5): 565–70. doi:10.1097/01.ftd.0000164610.14808.45. PMID16175127. S2CID45605607.
^Kintz P, Villain M, Concheiro M, Cirimele V (June 2005). "Screening and confirmatory method for benzodiazepines and hypnotics in oral fluid by LC-MS/MS". Forensic Science International. 150 (2–3): 213–20. doi:10.1016/j.forsciint.2004.12.040. PMID15944062.
^Laloup M, Fernandez M, Wood M, Maes V, De Boeck G, Vanbeckevoort Y, Samyn N (August 2007). "Detection of diazepam in urine, hair and preserved oral fluid samples with LC-MS-MS after single and repeated administration of Myolastan and Valium". Analytical and Bioanalytical Chemistry. 388 (7): 1545–56. doi:10.1007/s00216-007-1297-9. PMID17468852. S2CID19256926.